Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective

References

• Shepard HM, Phillips GL, Thanos CD, et al. Developments in therapy with monoclonal antibodies and related proteins. Clin Med. 2017 Jun;17(3):220–232.
   PubMed Web of Science ®Google Scholar
• Troein P, Newton M, Scott K, et al. The impact of biosimilar competition in Europe 2021. [ updated 2021 Dec; cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf
   Google Scholar
• Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars - the explanatory case of bevacizumab. Eur J Cancer. 2021 Jan;143:40–42.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency and European Commission. Biosimilars in the EU: information guide for healthcare professionals 2019. [ updated 2019 Oct 10; cited 2023 May 30]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
   Google Scholar
• Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020 Apr;34(2):159–170. doi: 10.1007/s40259-019-00395-w
   PubMed Web of Science ®Google Scholar
• Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther. 2019 Oct 03;19(10):1031–1043.
   PubMed Web of Science ®Google Scholar
• Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe 2011. [ updated 2023 May 12;cited 2023 May 30]. Available from: https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe
   Google Scholar
• European Medicines Agency and Heads of Medicines Agencies. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. [updated 2023 April 21; cited 2023 May 30]. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf
   Google Scholar
• Medicines for Europe. Market review - biosimilar medicines markets 2020: medicines for Europe. 2020. [updated 2021 Mar; cited 2023 May 30]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2021/03/Biosimilar%20Market%20Review-Final.pdf
   Google Scholar
• Moorkens E, Vulto AG, Kent J, et al. A look at the history of biosimilar adoption: characteristics of early and late adopters of infliximab and etanercept biosimilars in subregions of England, Scotland and Wales - a mixed methods study. BioDrugs. 2021 Jan;35(1):75–87.
   PubMed Web of Science ®Google Scholar
• Troein P, Newton M, Scott K. The impact of biosimilar competition in Europe 2020. [updated 2020 Dec; cited 2023 May 30]. Available from: https://health.ec.europa.eu/system/files/2021-01/biosimilar_competition_en_0.pdf
   Google Scholar
• National Prescription Drug Utilization Information System. Potential savings from biosimilars in Canada 2017. [updated 2018 May 2; cited 2023 May 30]. Available from: https://www.pmprb-cepmb.gc.ca/view.asp?ccid=1304
   Google Scholar
• de Vos Burchart H, Vulto VG. Programma Implementatie Biosimilars op Maat in ziekenhuizen (BOM) - Managementsamenvatting: Instituut Verantwoord Medicijngebruik; 2021 [updated 2021 Feb; cited 2023 May 30].
   Google Scholar
• May E, Taylor K. The cost-effectiveness of biosimilars and their future potential for the NHS, 2021. [updated 2021 May 21; cited 2023 Jul 23]. Available from: https://blogs.deloitte.co.uk/health/2021/05/the-cost-effectiveness-of-biosimilars-and-their-future-potential-for-the-nhs.html
   Google Scholar
• Simoens S, Cheung R. Tendering and biosimilars: what role for value-added services? J Mark Access Health Policy. 2020 Jan 01;8(1):1705120.
   PubMedGoogle Scholar
• Aitken M, Rodríguez I, Diamantara J, et al. Advancing biosimilar sustainability in Europe: a multi-stakeholder assessment 2018. [updated 2018 Sep 4; cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/advancing-biosimilar-sustainability-in-europe.pdf
   Google Scholar
• van Bodegraven AA, Süle A, Celano A, et al. How to realize the potential of off-patent biologicals and biosimilars in Europe? Guidance to policymakers. 2018 [cited 2023 May 30]. Available from: http://gabi-journal.net/how-to-realize-the-potential-of-off-patent-biologicals-and-biosimilars-in-europe-guidance-to-policymakers.html
   Google Scholar
• Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? PharmacoEconomics. 2016;34(6):609–616. doi: 10.1007/s40273-015-0380-x
   PubMed Web of Science ®Google Scholar
• Vulto A, Cheesman S, Gonzalez-McQuire S, et al. pbi56 sustianable biosimilar procurement in europe: a review of current policies and their potential impact. Value Health. 2019;22:S427. doi: 10.1016/j.jval.2019.09.160
   Web of Science ®Google Scholar
• Ferrario A, Dedet G, Humbert T, et al. Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ. 2020 Jan 13;368:l5444.
   PubMedGoogle Scholar
• NHS England. NHS set to save record £300 million on the NHS’s highest drug spend 2018. [updated 2018 Dec 6; cited 2023 May 30]. Available from: https://www.england.nhs.uk/2018/11/nhs-set-to-save-record-300-million-on-the-nhss-highest-drug-spend/
   Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147. doi: 10.1371/journal.pone.0190147
   PubMed Web of Science ®Google Scholar
• NHS England. Biosimilar medicines 2023. [cited 2023 May 30]. Available from: https://www.england.nhs.uk/medicines-2/biosimilar-medicines/
   Google Scholar
• The Canadian Agency for Drugs and Technologies in Health (CADTH). International policies on the appropriate use of biosimilar drugs. 2018 [updated 2018 Oct; cited 2023 May 30]. Available from: https://www.cadth.ca/sites/default/files/pdf/es0333_international-policies-on-use-of-biosimilar-drugs.pdf
   Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017 Jun 1;11(6):690–6. doi: 10.1093/ecco-jcc/jjw216
   PubMed Web of Science ®Google Scholar
• Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, et al. Qualitative analysis of the design and implementation of benefit-sharing programs for Biologics Across Europe. BioDrugs. 2022 Mar;36(2):217–229.
   PubMed Web of Science ®Google Scholar
• Troein P. Leveraging biosimilars for better access and lower cost, 2018 [updated 2021 Dec; cited 2023 Jul 11]. Available from: https://www.eahp.eu/sites/default/files/p._troein.pdf
   Google Scholar
• Bruce F. Can biosimilar orphans increase health system sustainability in the UK? 2021 [updated 2021, Jan 27; cited 2023 Jul 23]. Available from: https://pink.pharmaintelligence.informa.com/PS143672/Can-Biosimilar-Orphans-Increase-Health-System-Sustainability-In-The-UK
   Google Scholar
• Cornes P, Gascon P, Vulto AG, et al. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs. 2020;34(3):255–263. doi: 10.1007/s40259-020-00411-4
   PubMed Web of Science ®Google Scholar
• Jenkinson PW, Plevris N, Siakavellas S, et al. Temporal trends in surgical resection rates and biologic prescribing in Crohn’s disease: a population-based cohort study. J Crohns Colitis. 2020 Sep 16;14(9):1241–1247. doi: 10.1093/ecco-jcc/jjaa044
   PubMed Web of Science ®Google Scholar
• IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets 2016. [updated 2016 Mar; cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/delivering-on-the-potential-of-biosimilar-medicines.pdf
   Google Scholar
• NHS England. NHS saves £1.2 billion on medicines over three years 2022. [updated 2022, Jul 1; cited 2023 Jul 23]. Available from: https://www.england.nhs.uk/2022/07/nhs-saves-1-2-billion-on-medicines-over-three-years/
   Google Scholar
• NHS England. Innovative Medicines Fund. 2023 [cited 2023 Jul 23]. Available from: https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/
   Google Scholar
• NICE. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer 2019. [updated 2019 Mar 20; cited 2023 May 30]. Available from: https://www.nice.org.uk/guidance/TA569/chapter/1-Recommendations
   Google Scholar
• European Pharmaceutical Review. EC approves first high concentration, low-volume adalimumab biosimilar 2021. [updated 2021 Feb 16; cited 2023 May 30]. Available from: https://www.europeanpharmaceuticalreview.com/news/143114/ec-approves-first-high-concentration-low-volume-adalimumab-biosimilar-yuflyma/
   Google Scholar
• Businesswire. Celltrion healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17) 2021. [updated 2021 Feb 15; cited 2023 Feb 15]. Available from: https://www.businesswire.com/news/home/20210215005195/en/Celltrion-Healthcare-receives-European-Commission-EC-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-YuflymaTM-CT-P17
   Google Scholar
• Hanes V, Chow V, Stewart T, et al. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects. Cancer Chemother Pharmacol. 2021 Nov;88(5):879–886.
   PubMed Web of Science ®Google Scholar
• Celltrion Healthcare. Remsima®SC is the world’s first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA), Korean Ministry of Food and Drug Safety(MFDS) and Health Canada. 2019 [cited 2023 May 30]. Available from: https://www.celltrionhealthcare.com/en-us/products/remsimasc/
   Google Scholar
• European Medicines Agency. Remsima. Summary Of Product Charateristics. 2013 [updated 2023 May 30; cited 2023 May 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf
   Google Scholar
• Liu J, Sylwestrzak G, Ruggieri AP, et al. Intravenous versus subcutaneous anti-TNF-alpha agents for Crohn’s disease: a comparison of effectiveness and safety. J Manag Care Spec Pharm. 2015 Jul;21(7):559–566.
   PubMed Web of Science ®Google Scholar
• Simoens S, Vulto AG, Dylst P. Simulating costs of intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in adjuvant HER2-positive breast cancer: a Belgian case study. Pharmaceuticals. 2021;14(5):450. doi: 10.3390/ph14050450
   Web of Science ®Google Scholar
• Epstein RS. Payer perspectives on intravenous versus subcutaneous administration of drugs. Clinicoecon Outcomes Res. 2021;13:801–807. doi: 10.2147/CEOR.S317687
   PubMed Web of Science ®Google Scholar
• Weiser S, Burns C, Zartler ER. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera(TM)), a trastuzumab biosimilar, under extended in-use conditions. J Oncol Pharm Pract. 2023 Apr;29(3):590–600. doi: 10.1177/10781552221074649
   PubMed Web of Science ®Google Scholar
• Yun J, Kim J, Chung J, et al. Extended stability of reconstituted and diluted SB3 (trastuzumab biosimilar) assessed by physicochemical and biological properties. Adv Ther. 2019 Jul;36(7):1700–1714.
   PubMed Web of Science ®Google Scholar
• Paul M, Astier A, Vieillard V. Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures. GaBi J. 2018 [cited 2023 May 30]; 7 (3):101–110. doi: 10.5639/gabij.2018.0703.022
   Google Scholar
• European Medicines Agency. Trazimera. Summary Of Product Characteristics. 2018 [updated 2022 Oct 17; cited 2023 May 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/trazimera-epar-product-information_en.pdf
   Google Scholar
• de Mora F. Biosimilars: a value proposition. BioDrugs. 2019 Aug;33(4):353–356. doi: 10.1007/s40259-019-00360-7
   PubMed Web of Science ®Google Scholar
• NHS England. NHS England board paper. Best Value Biologicals: Adalimumab 2018. [updated 2018 Nov 28; cited 2023 May 30]. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/11/08-pb-28-11-2018-best-value-adalimumab-product-in-nhs.pdf
   Google Scholar
• Gils A. Combining therapeutic drug monitoring with biosimilars, a strategy to improve the efficacy of biologicals for treating inflammatory bowel diseases at an affordable cost. Dig Dis. 2017;35(1–2):61–68. doi: 10.1159/000449085
   PubMed Web of Science ®Google Scholar
• Raffaelli EA, Massimino F. Reference biological medicines (‘originators’) and ‘biosimilars’: competition and patient protection. Antitrust & Public Policies. 2018;4(2):128–177.
   Google Scholar
• Guntern R. 15 years of biosimilar access in Europe PharmaTimes online 2021. [updated 2021 May; cited 2023 May 30]. Available from: https://www.pharmatimes.com/magazine/2021/may_2021/15_years_of_biosimilar_access_in_europe
   Google Scholar
• Cherny N, Sullivan R, Torode J, et al. ESMO European consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016 Aug;27(8):1423–1443.
   PubMed Web of Science ®Google Scholar
• NICE. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy 2015. [updated 2015 Feb 25; cited 2023 May 30]. Available from: https://www.nice.org.uk/guidance/ta329/chapter/1-Guidance
   Google Scholar
• Samaan MA, Irving PM. The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. Expert Opin Biol Ther. 2016 Aug;16(8):975–977. doi: 10.1080/14712598.2016.1189529
   PubMed Web of Science ®Google Scholar
• Quintiles IMS. The impact of biosimilar competition in Europe. 2017 [cited 2023 May 30]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf
   Google Scholar
• Taylor PC, Askari A, Choy E, et al. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Med. 2023 Feb 14;21(1):55. doi: 10.1186/s12916-023-02746-5
   PubMed Web of Science ®Google Scholar
• NHS England. Clinical commissioning policy statement: rituximab bio-similar for the treatment of myasthenia gravis (adults). 2018 [updated 2021 Mar 25; cited 2023 Jul 23]. Available from: https://www.england.nhs.uk/wp-content/uploads/2021/04/Rituximab-biosimilar-for-the-treatment-of-myasthenia-gravis-adults-v2.pdf?UNLID=47063793820225187102
   Google Scholar
• NICE. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy, 2014 [updated 2018 April 26; cited 2023 July 23]. Available from: https://www.nice.org.uk/guidance/ta323
   Google Scholar
• Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: part 2-biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019 Jun;33(3):299–306.
   PubMed Web of Science ®Google Scholar
• IQVIA. Country scorecards for biosimilar sustainability: methodology appendix 2020. [updated 2020 Jun; cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/country-scorecards-for-biosimilar-sustainability/iqvia-institute-scorecards-appendix-orb2520.pdf
   Google Scholar
• IQVIA. Biosimilar Scorecard 2020: Romania. 2020. [cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/country-scorecards-for-biosimilar-sustainability/iqvia-biosimilar-scorecard-romania.pdf?la=en&_=1621259055784
   Google Scholar
• Ministère des solidarites et de la Santé. Stratégie nationale de santé 2018-2022. 2017 [cited 2023 May 30]. Available from: https://sante.gouv.fr/IMG/pdf/dossier_sns_2017_vdef.pdf
   Google Scholar
• IQVIA. Biosimilar scorecard 2020: Norway. 2020 [cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/country-scorecards-for-biosimilar-sustainability/iqvia-biosimilar-scorecard-norway.pdf?la=en
   Google Scholar